X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dr. Reddys with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs TEVA PHARMA (Israel) - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   TEVA PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
TEVA PHARMA
Dec-13
DR. REDDYS LAB/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3972,848-   
Low Rs2,5602,474-   
Sales per share (Unadj.) Rs856.51,634.2-  
Earnings per share (Unadj.) Rs78.0102.1-  
Cash flow per share (Unadj.) Rs139.9234.2-  
Dividends per share (Unadj.) Rs20.0089.37-  
Dividend yield (eoy) %0.73.4 20.0%  
Book value per share (Unadj.) Rs739.81,815.3-  
Shares outstanding (eoy) m165.74848.00-   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.51.6 213.6%   
Avg P/E ratio x38.226.1 146.6%  
P/CF ratio (eoy) x21.311.4 187.4%  
Price / Book Value ratio x4.01.5 274.7%  
Dividend payout %25.787.5 29.3%   
Avg Mkt Cap Rs m493,6322,256,172 21.9%   
No. of employees `00022.744.9 50.5%   
Total wages/salary Rs m31,0680-   
Avg. sales/employee Rs Th6,259.030,833.7 20.3%   
Avg. wages/employee Rs Th1,369.80-   
Avg. net profit/employee Rs Th569.71,926.2 29.6%   
INCOME DATA
Net Sales Rs m141,9611,385,821 10.2%  
Other income Rs m1,7150-   
Total revenues Rs m143,6761,385,821 10.4%   
Gross profit Rs m24,722379,508 6.5%  
Depreciation Rs m10,266112,017 9.2%   
Interest Rs m63427,220 2.3%   
Profit before tax Rs m15,537240,271 6.5%   
Minority Interest Rs m01,092 0.0%   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m0-157,725 0.0%   
Tax Rs m2,965-2,933 -101.1%   
Profit after tax Rs m12,92186,571 14.9%  
Gross profit margin %17.427.4 63.6%  
Effective tax rate %19.1-1.2 -1,563.1%   
Net profit margin %9.16.2 145.7%  
BALANCE SHEET DATA
Current assets Rs m96,837935,978 10.3%   
Current liabilities Rs m84,199816,252 10.3%   
Net working cap to sales %8.98.6 103.0%  
Current ratio x1.21.1 100.3%  
Inventory Days Days7391 80.8%  
Debtors Days Days9896 101.8%  
Net fixed assets Rs m102,552452,640 22.7%   
Share capital Rs m8293,411 24.3%   
"Free" reserves Rs m121,7920-   
Net worth Rs m122,6211,539,384 8.0%   
Long term debt Rs m5,449708,601 0.8%   
Total assets Rs m218,1653,167,045 6.9%  
Interest coverage x25.59.8 259.6%   
Debt to equity ratio x00.5 9.7%  
Sales to assets ratio x0.70.4 148.7%   
Return on assets %6.23.6 172.9%  
Return on equity %10.55.6 187.4%  
Return on capital %12.94.9 261.6%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Net fx Rs m55,3150-   
CASH FLOW
From Operations Rs m21,444220,828 9.7%  
From Investments Rs m-18,404-78,248 23.5%  
From Financial Activity Rs m-3,692-264,898 1.4%  
Net Cashflow Rs m-1,144-122,318 0.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 68.22 Rs / USD

Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare DR. REDDYS LAB With: AJANTA PHARMA  SUVEN LIFE  ORCHID PHARMA LTD  VENUS REMEDIES  AUROBINDO PHARMA  



Today's Market

Of Analysis of IPOs Launched in 2018, Governments Effort to Boost Aviation Infrastructure and Key Stocks in Action Today(Pre-Open)

The returns from initial public offers (IPOs) launched in 2018 are mixed. Comparing the gain/ (loss) since the listing date as mentioned in the last column, seven stocks are in the negative territory.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jun 21, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS